Efficacy and Safety of a 0.1% Tacrolimus Nasal Ointment as a Treatment for Epistaxis in Hereditary Hemorrhagic Telangiectasia: A Double-Blind, Randomized, Placebo-Controlled, Multicenter Trial

Hereditary hemorrhagic telangiectasia is a rare but ubiquitous genetic disease. Epistaxis is the most frequent and life-threatening manifestation and tacrolimus, an immunosuppressive agent, appears to be an interesting new treatment option because of its anti-angiogenic properties. Our objective was to evaluate, six weeks after the end of the treatment, the efficacy on the duration of nosebleeds of tacrolimus nasal ointment, administered for six weeks to patients with hereditary hemorrhagic telangiectasia complicated by nosebleeds, and we performed a prospective, multicenter, randomized, placebo-controlled, double-blinded, ratio 1:1 phase II study. Patients were recruited from three French Hereditary Hemorrhagic Telangiectasia (HHT) centers between May 2017 and August 2018, with a six-week follow-up, and we included people aged over 18 years, diagnosed with hereditary hemorrhagic telangiectasia and epistaxis (total duration > 30 min/6 weeks prior to inclusion). Tacrolimus ointment 0.1% was self-administered by the patients twice daily. About 0.1 g of product was to be administered in each nostril with a cotton swab. A total of 50 patients was randomized and treated. Mean epistaxis duration before and after treatment in the tacrolimus group were 324.64 and 249.14 min, respectively, and in the placebo group 224.69 and 188.14 min, respectively. Epistaxis duration improved in both groups, with no significant difference in our main objective comparing epistaxis before and after treatment (p = 0.77); however, there was a significant difference in evolution when comparing epistaxis before and during treatment (p = 0.04). Toxicity was low and no severe adverse events were reported. In conclusion, tacrolimus nasal ointment, administered for six weeks, did not improve epistaxis in HHT patients after the end of the treatment. However, the good tolerance, associated with a significant improvement in epistaxis duration during treatment, encouraged us to perform a phase 3 trial on a larger patient population with a main outcome of epistaxis duration during treatment and a longer treatment time.

[1]  Liang‐Kung Chen,et al.  Hereditary hemorrhagic telangiectasia. , 2020, Zhonghua yi xue za zhi = Chinese medical journal; Free China ed.

[2]  S. Dupuis-Girod,et al.  Future treatments for hereditary hemorrhagic telangiectasia , 2020, Orphanet Journal of Rare Diseases.

[3]  W. Seeger,et al.  Treatment with low-dose tacrolimus inhibits bleeding complications in a patient with hereditary hemorrhagic telangiectasia and pulmonary arterial hypertension , 2018, Pulmonary circulation.

[4]  F. Campagne,et al.  Tacrolimus rescues the signaling and gene expression signature of endothelial ALK1 loss-of-function and improves HHT vascular pathology , 2017, Human molecular genetics.

[5]  C. Merlo,et al.  Effect of Topical Intranasal Therapy on Epistaxis Frequency in Patients With Hereditary Hemorrhagic Telangiectasia: A Randomized Clinical Trial. , 2016, JAMA.

[6]  B. Gilbert-Dussardier,et al.  Effect of Bevacizumab Nasal Spray on Epistaxis Duration in Hereditary Hemorrhagic Telangectasia: A Randomized Clinical Trial. , 2016, JAMA.

[7]  C. Merlo,et al.  The minimal important difference of the epistaxis severity score in hereditary hemorrhagic telangiectasia , 2016, The Laryngoscope.

[8]  A. Singal,et al.  Clinical and serological efficacy of topical calcineurin inhibitors in oral lichen planus: a prospective randomized controlled trial , 2016, International journal of dermatology.

[9]  S. Bailly,et al.  Emerging roles of BMP9 and BMP10 in hereditary hemorrhagic telangiectasia , 2015, Front. Genet..

[10]  P. Arduino,et al.  Pimecrolimus vs. tacrolimus for the topical treatment of unresponsive oral erosive lichen planus: a 8 week randomized double‐blind controlled study , 2014, Journal of the European Academy of Dermatology and Venereology : JEADV.

[11]  D. Bernstein,et al.  FK506 activates BMPR2, rescues endothelial dysfunction, and reverses pulmonary hypertension. , 2013, The Journal of clinical investigation.

[12]  J. Saurin,et al.  Bevacizumab in patients with hereditary hemorrhagic telangiectasia and severe hepatic vascular malformations and high cardiac output. , 2012, JAMA.

[13]  F. Sanz‐Rodríguez,et al.  Immunosuppressor FK506 Increases Endoglin and Activin Receptor-Like Kinase 1 Expression and Modulates Transforming Growth Factor-β1 Signaling in Endothelial Cells , 2011, Molecular Pharmacology.

[14]  S. Dupuis-Girod,et al.  Hereditary hemorrhagic telangiectasia: from molecular biology to patient care , 2010, Journal of thrombosis and haemostasis : JTH.

[15]  C. Mummery,et al.  Thalidomide stimulates vessel maturation and reduces epistaxis in individuals with hereditary hemorrhagic telangiectasia , 2010, Nature Medicine.

[16]  C. Merlo,et al.  An epistaxis severity score for hereditary hemorrhagic telangiectasia , 2010, The Laryngoscope.

[17]  J. Saurin,et al.  Long‐term outcome of patients with hereditary hemorrhagic telangiectasia and severe hepatic involvement after orthotopic liver transplantation: A single‐center study , 2010, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[18]  M. Mäkelä,et al.  The pharmacokinetics of tacrolimus after first and repeated dosing with 0.03% ointment in infants with atopic dermatitis * , 2009, International journal of dermatology.

[19]  N. Martinelli,et al.  Comparative effect of tacrolimus 0.1% ointment and clobetasol 0.05% ointment in patients with oral lichen planus. , 2008, Journal of clinical periodontology.

[20]  Y. Liao,et al.  Comparison of cutaneous tolerance and efficacy of calcitriol 3 μg g−1 ointment and tacrolimus 0·3 mg g−1 ointment in chronic plaque psoriasis involving facial or genitofemoral areas: a double‐blind, randomized controlled trial , 2007, The British journal of dermatology.

[21]  A. Hrõbjartsson,et al.  Blinded trials taken to the test: an analysis of randomized clinical trials that report tests for the success of blinding. , 2007, International journal of epidemiology.

[22]  P. Falkai,et al.  Health-Related Quality of Life in Hereditary Hemorrhagic Telangiectasia , 2005, Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery.

[23]  N. Undre,et al.  A multicenter study of the pharmacokinetics of tacrolimus ointment after first and repeated application to children with atopic dermatitis. , 2005, The Journal of investigative dermatology.

[24]  Wolzt,et al.  World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. , 2003, The Journal of the American College of Dentists.

[25]  A. Guttmacher,et al.  Hereditary hemorrhagic telangiectasia. , 1995, The New England journal of medicine.

[26]  Christiane,et al.  World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. , 2013, JAMA.

[27]  J. Honnorat,et al.  Genotype-phenotype correlations in hereditary hemorrhagic telangiectasia: Data from the French-Italian HHT network , 2007, Genetics in Medicine.

[28]  Christiane,et al.  World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. , 2004, Journal international de bioethique = International journal of bioethics.